Compare prices and buy Thymalin from 5 research peptide vendors - also called suppliers or sources. Updated daily.
A polypeptide extract of calf thymus (CAS 79621-14-0) obtained by mild acid extraction, developed in the Soviet Union by Vladimir Khavinson and Vyacheslav Morozov. It is a mixture of peptides rather than a single sequence, and its developers report that it acts on T-cell differentiation. The dipeptide Thymogen (Glu-Trp) was isolated from it as one of its active components. Registered in Russia as a prescription medicine, and not FDA-approved.
For research purposes only. Not medical advice.
Thymalin is a tissue extract, not a single molecule. A 2021 paper from Vladimir Khavinson's Saint Petersburg Institute of Bioregulation and Gerontology describes it as a complex of peptides isolated from calf thymus, with a molecular weight of up to 10 kDa. The same paper names its active components as two dipeptides, Glu-Trp and Lys-Glu, and a tripeptide, Glu-Asp-Pro. Synthetic versions of those short peptides have their own pages here: Thymogen is Glu-Trp, Vilon is Lys-Glu, and Crystagen is the compound its developers list as Glu-Asp-Pro.
Thymalin belongs to Khavinson's bioregulator program, whose organizing hypothesis, that very short peptides regulate gene expression in the tissue they come from, is set out on the Epitalon page. It also runs parallel to American work on calf thymus extracts that produced thymosin alpha-1. The difference is that thymosin alpha-1 is one defined sequence, while Thymalin remains the extract.
Two recent laboratory papers from the developers' institute set out the proposed mechanism. In a 2020 study in Bulletin of Experimental Biology and Medicine, Thymalin reduced expression of the markers CD44 and CD117 on human hematopoietic stem cells by two to three times and raised expression of CD28, a marker of mature T cells, 6.8-fold. The authors read this as a push toward T-cell differentiation.
A 2023 paper in the International Journal of Molecular Sciences combined computer docking of the Lys-Glu and Glu-Trp dipeptides against DNA with a cell experiment. In human blood mononuclear cells stimulated with bacterial lipopolysaccharide, Thymalin and the two dipeptides reduced production of the inflammatory cytokines IL-1β, IL-6 and TNF-α by 1.4 to 6.0 times, using blood from four donors. Both are cell and modeling results, not clinical data.
A 2003 paper in Neuroendocrinology Letters by Khavinson and Morozov reported six to eight years of follow-up in 266 elderly people, assessed by their institute and the Institute of Gerontology in Kiev, across several treatment groups and a control group. Mortality over the observation period was reported as 2.0 to 2.1 times lower in the Thymalin group than in the control group. The abstract does not describe how participants were assigned to groups, and the authors are the drug's developers.
A 2021 paper in Stem Cell Reviews and Reports describes a single-center, open-label, randomized trial at St. Petersburg City General Hospital No. 2 in 2020. Forty-two hospitalized COVID-19 patients received Thymalin alongside standard care and 50 received standard care alone. No patient in either group died. The reported figures are laboratory markers compared with each group's own pre-treatment values: C-reactive protein fell 9.7-fold in the Thymalin group and 1.7-fold in the control group. The authors include the developers' institute, and the paper names no funding source.
In Russia, Thymalin is a registered medicine. The 2021 paper states it has been approved there for medical use since 1982 and is manufactured by Samson-Med in St. Petersburg.
In the United States it holds no approval. A check on October 21, 2026 found it in none of the following:
Indexed listings use the name Thymalin itself, so there is no code name to decode. The vendors' descriptions of the material differ. As of October 21, 2026, ION Peptide's page describes a peptide complex derived from thymic tissue extracts. Trulab Peptides calls it a synthetic peptide originally isolated from the thymus gland. Peptide Titans describes a polypeptide complex derived from thymic tissue in its specifications, calls it a synthetic peptide research compound in its storage notes, and lists the molecular formula and weight as variable. None of these pages states an animal source or a sequence.
An extract is defined by the tissue it comes from and cannot be produced by peptide synthesis, so "synthetic" and "extract" describe different materials. Only a lot's certificate of analysis can say what a given vial holds. The Immune & Anti-inflammatory category page covers how to read a per-milligram price on an extract.
No. Thymalin is an extract of calf thymus, a mixture of peptides rather than one defined sequence. A 2021 paper from its developers' institute describes it as a complex of peptides with a molecular weight of up to 10 kDa and names two dipeptides, Glu-Trp and Lys-Glu, and a tripeptide, Glu-Asp-Pro, as its active components.
In Russia, yes. A 2021 paper from its developers states it has been approved for medical use there since 1982 and is manufactured by Samson-Med in St. Petersburg. In the United States it is not approved. As of October 21, 2026 it had no application in FDA's drugsfda database and did not appear on FDA's 503A or 503B bulk drug substance nomination lists.
Vendor descriptions differ. As of October 21, 2026, one indexed vendor's page described a synthetic peptide, another a peptide complex derived from thymic tissue, and a third used both descriptions on the same page. None stated an animal source or a sequence. The registered drug is a calf thymus extract, and an extract is defined by its tissue source rather than made by synthesis, so only a lot's certificate of analysis can say what a given vial holds.
Two examples come from its developers' institute. A 2003 paper reported mortality 2.0 to 2.1 times lower than in a control group over six to eight years of follow-up in elderly people, and its abstract does not describe how participants were assigned to groups. A 2021 single-center, open-label, randomized trial in 92 hospitalized COVID-19 patients reported no deaths in either group, and C-reactive protein fell 9.7-fold from pre-treatment levels with Thymalin added to standard care, against 1.7-fold with standard care alone. ClinicalTrials.gov listed no registered Thymalin study as of October 21, 2026.
Thymalin is sold by 5 research peptide vendors indexed on PeptideScouter, with 5 tracked listings compared per vendor in the table above. Pricing is normalized and refreshed daily.
4 of the 5 indexed vendors currently have Thymalin in stock. The comparison table marks out-of-stock listings, and stock state is refreshed daily.
Peptide Titans currently lists Thymalin at $3.50/mg, the lowest listed price across 5 tracked research peptide vendors. With current vendor discount codes applied, the lowest effective price is $3.15/mg.
Discount codes are issued per vendor rather than per peptide, so any code applies across that vendor's whole catalog. All 5 vendors listing Thymalin publish a PeptideScouter code, worth 10% to 15% off. Applied, the lowest effective price falls from $3.50/mg listed to $3.15/mg at Peptide Titans. Each vendor's code is shown beside its price in the table above.
Thymalin ranges from $3.50/mg to $5.90/mg across 5 listings from 5 research peptide vendors, normalized to USD per milligram and refreshed daily.
5 research peptide vendors currently list Thymalin on PeptideScouter, with 4 in stock right now. We track 5 listings across size and kit variants.
Thymalin's CAS Registry Number is 79621-14-0.
